Sign up for FREE access to our Commentary & Past Stock Picks
Today we highlight a Biotechnology stock listed on Nasdaq. The CymorFund Blog is a subscription service. Blogs about stock picks we add to our portfolio are available immediately only to Premium subscribers. All Subscribers have immediate access to the other categories of our Blogs, including Stock Picks that we have sold.
Inovio Pharmaceuticals, Inc. (INO)
Inovio trades on Nasdaq. The stock listed in 1999 with the hope of revolutionizing the way some illnesses, especially cancer, are treated. There were high hopes for this stock, but like all bio stocks, it takes a very long time from the formation of an idea, to the final approval. Below is a chart of the troubled fluctuations in INO. Almost a reverse hockey stick pattern.
As is illustrated, initial high hopes turned into dismay after delay after delay. However the company persisted, believing they had the next best big idea, and after the stock meandered around the $2.00 level for a couple of years, investors started to take notice, especially when the big Pharma companies started funding studies with INO.
In April 2013, Inovio Pharmaceuticals was recognized with “Best Therapeutic Vaccine” and “Best Early Stage Biotech” Awards at the World Vaccine Congress. People started to take notice again.
In September 2013, INO partnered with Roche on Inovio’s prostate cancer and hepatitis B immunotherapy products. Now the stock really started to move, eventually hitting almost $15. Then in November 2014, a really bad shock.
“Inovio Pharmaceuticals, Inc. announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio’s DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer.”
INO had raised a large amount of cash in a public offering and felt it had enough cash to carry on, and said it would. The stock started to drift down, dropping almost to $6 in February 2015. Investors were dismayed.
However, INO carried on with further announcements and further advances, and the stock started a rapid rise, almost doubling in the last two months. The world is again noticing Inovio.
What Does INO Do?
We quote Inovio – “The achievements of stimulating the immune system through vaccination have been profound, saving millions from sickness and death. Inovio is advancing breakthroughs to extend this legacy to many of today’s challenging diseases. Our synthetic vaccines are designed to treat as well as prevent illness, aiming to break the body’s tolerance of cancerous cells and protect against diverse, changing strains of infectious diseases. Inovio is revolutionizing vaccines!”
“Revolutionizing the Fight Against Cancers and Infectious Diseases It’s All About the T-Cells” Follow this link to the company’s website.
To describe the company, we use the Yahoo Finance description. Follow this link to get Yahoo’s analysis on the company. “Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The companys SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola”
| Insider Transactions Reported – Last Two Years |
|---|
|
| Data provided by EDGAR Online |
Added INO to Our Portfolio – $10.38 (US$)
We today added Inovio to our portfolio. Analysts have varying views on the company, with the average analyst opinion on Yahoo Finance being a target of $20.80. If the company makes a breakthrough, the stock could really move. On the other hand, INO has various trials in Stage I, Stage II, & entering Stage III. Disappointment in a trial could see a plunging stock value. This stock is not for the faint of heart. Bio stocks have a history of disappointing investors.
This website and authors’ opinions are intended to be informative, but information contained is not guaranteed as being accurate or a complete statement or summary of available data. We assume no responsibility for errors, omissions, or contrary interpretation of the subject matter herein. Any perceived slights, omissions, or mis-statements of persons, peoples, or organizations or other published materials are unintentional. This information is not intended for use as a source of legal, business, accounting or financial advice, & readers are advised to seek services of competent professionals. No representation is made or implied that the reader will do well from using the suggested techniques, strategies, methods, systems, or ideas; rather information is presented for news value only. We do not assume any responsibility or liability whatsoever for what you choose to do with this information.
We may or may not have positions in securities we name. In making an investment decision consider numerous factors such as portfolio balancing, timing, cash and capital reserves, asset allocation and other. Do your own research. Matters discussed contain forward-looking statements that are subject to risks and uncertainties and actual results may differ materially from any future results, performance or achievements expressed or implied. Views expressed are opinions and not investment advice. You should retain a licensed professional to guide you. This report is neither a solicitation nor a recommendation to buy or sell securities. We are not a registered investment advisor nor a broker-dealer.
